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The Division of HIV/AIDS Prevention at the Centers for Disease Control and Prevention (CDC) 
was charged by the National HIV/AIDS Strategy to provide “technical assistance to [HIV 
reporting] localities to collect data to calculate community viral load” [1]. Guidance on 
Community Viral Load: A Family of Measures, Definitions, and Method for Calculation 
represents the work of over 50 Workgroup members from more than 25 jurisdictions. This 
Guidance document introduces the concept of community viral load and provides definitions of, 
and methods for calculating, community viral load and related measures. 
During the past few years, there has been great interest in the scientific literature and at scientific 
meetings about a new public health HIV measure called “community viral load.” It is a 
population-based measure of HIV-infected individuals’ concentration of plasma HIV-1 RNA 
(viral load). When viral loads are summed across a community and then divided by the number 
of HIV-infected persons in the community, the average HIV community viral load represents the 
level of viremia for a geographic area during a defined time. Having a single number that is an 
indicator of HIV transmission potential and quality of HIV care and treatment for a geographic 
area is extremely attractive. 
For community viral load to be a robust measurement, it must reflect the viral loads of persons 
diagnosed with HIV, be a reliable measure that is also sensitive to viral load changes in the 
community, and reflect sexual behaviors or other HIV transmission risks in the community. This 
measure could be used by local HIV reporting jurisdictions each year to assess progress in 
treating HIV-infected persons with antiretroviral medications that would lower the community’s 
viremia, which could—potentially—reduce transmission within the community. Community 
viral load may also have some utility in monitoring the progress of national HIV care and 
treatment objectives when assessed over time. 
During the process of examining local and federal HIV surveillance activities and the data 
obtained from such activities, a number of issues were identified that may impact the ability of a 
jurisdiction to successfully and accurately estimate a population’s viral load. These include: 
 Population selection. A well-defined population should be chosen, possibly even a closed 
population, so that those who are at risk for transmitting HIV and those at risk for 
acquiring HIV can be identified and counted, all within a defined geographic area that 
may not correspond with jurisdictional boundaries. 
 Varying definitions of “community viral load.” There are many analyses that report 
“community viral load” and the methods and definitions used for each varies somewhat. 
The history of the community viral load concept and an inventory of community viral 
load analyses highlight these differences and the varying methods used to calculate 
community viral load (Appendix A and Table 2). Ideally, measures of community viral 
load and its related terms should use a common method that would, at a minimum, allow 
for periodic snapshots to assess changes over time by a jurisdiction, as well as allow for 
comparisons across localities. 
 Complete and accurate surveillance/health data. Locations with universal health coverage 
or a common source of healthcare will fare better than those areas without such 
infrastructure because the latter will need to create composite data from disparate 
sources. In addition, jurisdictions have reported significant amounts of missing viral load 
results for HIV-infected persons, which may bias community viral load estimates. This 
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may be due to a large proportion of HIV-infected persons being out of care in a 
jurisdiction, or data quality issues for a jurisdiction, or both. 
This document proposes a family of viral load measurements, of which one is Community Viral 
Load (Figure 2); other measures include: Population Viral Load, In-Care Viral Load, and 
Monitored Viral Load. Technical guidance for estimating Community Viral Load, In-Care Viral 
Load, and Monitored Viral Load are provided. Analytic methods and tools (spreadsheet and SAS 
code) for calculating mean viral load, percentage with suppressed viral load (≤200 copies/mL), 
percentage with undetectable viral load (≤50 copies/mL), and for assessing a statistical 
difference between two mean viral load measures will be made available by CDC to HIV 
surveillance coordinators. While this Guidance document is intended primarily for HIV 
surveillance coordinators to be able to calculate Community Viral Load measures for their 
jurisdictions, it should be recognized that the ability to do so does not rest solely with the HIV 
surveillance system (see Appendix B for description of surveillance and viral load issues). Using 
viral load measures to monitor the epidemic is a function of policy, care and treatment, and 
surveillance as illustrated below: 
 
The effective monitoring of Community Viral Load measures and ultimately documenting 
progress towards the National HIV/AIDS Strategy goals of reduced HIV incidence and improved 
health outcomes for persons living with HIV infection in the United States (see Appendix E) 
requires translation of concepts developed in a few jurisdictions to relevant measures that can be 
used in all jurisdictions. This document acknowledges the complexity of doing so and offers 
practical options for measurements under various scenarios where policy, practice, and 
surveillance intersect.  
 
Policy 
 HIV treatment guidelines (when/how often viral load test recommended; see 
Appendixes C and D) 
 Reporting policies for laboratory tests (vary by jurisdiction) 
 Jurisdictional data sharing 
 Sharing surveillance data across jurisdictions  
 Facilities and institutions (private, federal) sharing data with surveillance  
Practice 
 Medical care practice of requesting viral load tests  
 Laboratory reporting practices and number of laboratories in a jurisdiction 
 Reach of HIV testing and linkage to care programs 
Surveillance 
 Entry/upload of laboratory reports 
 Death ascertainment 
 Deduplication of records (intra- and interstate) 
 Missing data 
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History of Community Viral Load  
In early 2009, based on a mathematical model for South Africa, Granich et al. suggested that 
universal HIV testing and immediate treatment with antiretroviral medications among persons 
with heterosexually acquired HIV infection could lead to virtual elimination of HIV disease in 50 
years [2]. The underlying mechanism by which this could be possible is to reduce the amount of 
virus circulating in a person’s bloodstream (HIV plasma viral load) by consistent and early use 
of antiretroviral medications. As the level of viremia and viral shedding decreases, infectiousness 
also decreases, greatly reducing or eliminating the transmission of HIV [3,4]. A 2004 study in 
Taiwan demonstrated that free access to HIV antiretroviral medications for HIV-infected persons 
decreased HIV transmission [5].  
The earliest use of “community viral load” occurred in 2008 at the Conference of Retroviruses 
and Opportunistic Infections by Ronald Stall [6]. Based on the work of Millett et al. [7], the high 
prevalence of untreated HIV infection was used to explain the disproportionately high rates of 
HIV infection among African American men who have sex with men (MSM). Due to lack of 
treatment and a resulting high viremia, the African American MSM community was described to 
have a much higher “community viral load” than other MSM communities, which accounted for 
more efficient transmission of HIV and higher infection rates.  
One of the first cohort studies to examine HIV concentration levels in the blood of injecting drug 
users (IDUs) from Vancouver, Canada was published in 2009 [8]. Wood et al. studied a well-
described population of IDUs that was followed every six months for more than 11 years. HIV 
viral loads, HIV diagnostic testing, and antiretroviral therapy were monitored for this population 
and community plasma HIV-1 RNA concentrations over time were ascertained. A statistically 
significant correlation between the median IDU community viral load and the incidence of new 
HIV infections was observed. Furthermore, in their analysis, Wood found that when the 
community viral load among IDUs decreased to <20,000 copies/mL, the association with HIV 
incidence ceased. 
In June 2010, Das et al. published a paper on community viral load in San Francisco [9]. Das and 
colleagues found a significant association between a declining community viral load and a 
decline in new HIV diagnoses from 2004 to 2008. Additionally, the authors presented viral load 
data in novel ways that examined geographic distribution of mean viral load by demographic, 
risk, and socioeconomic factors. Montaner et al. (2010) published data that helped provide the 
final link in the mechanism that described viral loads and transmission [10]. Using the 
community of British Columbia, Canada, they demonstrated that, over time, increased use of 
antiretroviral therapy was associated with a decrease in the population’s viral load and, 
ultimately, a decrease in new HIV infections. 
Collectively, these papers have galvanized the HIV prevention and surveillance communities and 
spurred analyses exploring the relationship between community viral load and newly diagnosed 
and reported cases and estimated HIV incidence (see Appendix A, Inventory of VL Analyses). 
In addition to ecological analyses suggesting benefits of reduction in community viral load for 
population-level HIV prevention, use of antiretroviral therapy by the HIV seropositive partner 
has been shown to be associated with lower HIV incidence in the seronegative partner [3, 11]. 
Data from the HIV Prevention Trials Network (HPTN) 052/AIDS Clinical Trials Group (ACTG) 
5245 have also found that antiretroviral treatment of an HIV-infected partner reduced 
transmission to the uninfected partner [4]. These data lend support to the Test-and-Treat 
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strategy [12, 13] that proposes to decrease HIV transmission through the following two 
pathways: 
 HIV testing identifies HIV-infected persons who, after learning their status, adopt safer 
behaviors, which decreases HIV transmission [14]. 
 HIV-infected individuals who initiate antiretroviral treatment, maintain high levels of 
adherence, and achieve viral suppression are less infectious, which decreases HIV 
transmission. 
 
To optimize health outcomes, however, 
expanded testing efforts must be coupled 
with initiatives that ensure the newly 
diagnosed and those already known to have 
HIV infection are effectively linked to HIV 
care [15], receive antiretroviral treatment as 
indicated, and achieve optimal adherence 
and suppression of viral replication. (See 
Appendix D.)
Figure 1. Test and Treat concept 
 
 
A recently launched National Institutes of Health (NIH) and CDC-supported study, HPTN065 
(TLC-Plus), aims to evaluate the feasibility of an enhanced community-level test, link to care, 
plus treat strategy in the United States. The study is being conducted in two intervention 
communities (the Bronx, New York and Washington, D.C.) and four non-intervention 
communities (Chicago, Illinois; Houston, Texas; Miami, Florida; and Philadelphia, 
Pennsylvania). HIV test sites that identify new HIV-infected patients will be randomized to one 
of two interventions: 1) financial incentives or 2) standard-of-care. Each intervention will be 
assessed for success in linkage to HIV care and for achieving and maintaining viral suppression 
among these newly diagnosed patients. The study outcomes will be evaluated using jurisdictional 
and national HIV surveillance data. Results from this 3-year study are expected in 2013. 
Appendix F includes a list of Test and Treat clinical trials. 
Given the interest in, and utility of, measurement of community viral load for monitoring HIV 
infections, it is critical to have guidelines so that various measures are comparable across time 
and across jurisdictions. These guidelines form the basis for CDC’s evaluation of the National 
HIV/AIDS Strategy goals and can be used to evaluate local Test and Treat initiatives. 
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Establishing a Common Language 
Researchers have interpreted community viral load differently (see Table 2 and Appendix A, 
Inventory of VL Analyses). Related community viral load terms and measures are being 
developed and it is not the intent of this document to catalogue each one. Instead, this document 
will propose some basic common language to encompass the original spirit and aspiration of 
HIV prevention, and suggest some measures or indicators from HIV surveillance that could be 
used by localities or by the nation, over time, as snapshots of primary, secondary, and tertiary 
HIV prevention efforts. Figure 2, Conceptual framework for viral load measurements among 
HIV-infected persons, depicts the four proposed Measures (capital M) of viral load (VL) for a 
given HIV-infected population and their component and categorical VL measures (lowercase m). 
Component VL measures include: A. In care and with undetectable VL; B. In care with 
detectable VL; C. In care, no VL; D. Diagnosed but not in care; and E. Undiagnosed. Categorical 
measures of viral load are described in the Technical Guidance section. 
Population Viral Load is a conceptual Measure, unable to be directly calculated, that includes 
viral loads of all HIV-infected persons in the population, both those unaware of their HIV status 
(undiagnosed) and those who are aware of their HIV status (diagnosed), whether or not linked 
and retained in HIV care. Population Viral Load is the most comprehensive Measure of the HIV 
transmission potential for a given population. Population Viral Load Measure could apply, in 
principle, to the whole nation, individual states, and specific jurisdictions; however, viral load 
measurements for subgroups depicted in boxes C, D, and E in Figure 2 are typically not available 
in the local or national HIV surveillance databases. The shortcomings of available data and 
nascent methodology for its modeling (including data imputations for persons in boxes C–E in 
Figure 2), has precluded the estimation of Population Viral Load to date. An estimated 21% of 
HIV-infected Americans are living with undiagnosed HIV infection [16] (box E, Figure 2) and, 
thus, their HIV viral loads are unknown but are likely detectable and elevated in the absence of 
antiretroviral therapy. These persons, who may practice unsafe sex while unaware of their HIV 
infection, are thought to contribute to the majority of new, sexually acquired HIV infections in 
the United States [17]. 
Viral load data are not available for all persons that have been diagnosed with HIV infection. A 
significant proportion of such persons are not in care at a given point in time (either never linked 
to HIV care or not retained in continuous care) and, therefore, may not have HIV viral load 
monitoring performed (box D, Figure 2). It can be assumed that most of these persons have 
detectable/not suppressed viral loads as they are unlikely to be receiving continuous, effective 
antiretroviral therapy; however, the actual distribution of their viral loads is not known (in the 
absence of special studies). Finally, a fraction of persons that are in care may be missing HIV 
viral load in HIV surveillance for a variety of reasons, including: incomplete or delayed 
reporting of viral loads from laboratories to the surveillance system, undetectable viral loads not 
reportable, viral load results that have not been entered into the surveillance database, patient 
refusal of HIV disease monitoring, receiving medical care but out of HIV care, and no viral load 

















Estimates based on national projections and may vary across U.S. states and jurisdictions. Relative sizes of each box are approximated from Gardner et al., Clin Infect Dis, 2011 and Burns et 






































The VL of persons in care but lacking VL in surveillance data represent a heterogeneous group. 
Persons that are missing VL results because of surveillance processes (e.g., VL results that haven’t 
been entered in the surveillance database) may have VL results similar to other persons in care and 
with VL results, whereas persons missing VL because they are refusing VL monitoring may have 
high VL, especially if they are also refusing antiretroviral therapy. To minimize the size and 
heterogeneity of persons in care but without VL, local health departments should work closely with 
the laboratories to assess, improve, and maintain the inflow of data and should promote policies for 
reporting of all detectable and undetectable HIV viral loads to surveillance systems.  
Community Viral Load describes viral load of all HIV-infected persons diagnosed with HIV 
infection in a given population. As with “Population Viral Load,” viral load measurements for 
persons that are ‘diagnosed but not in care’ (box D, Figure 2) are typically missing as is information 
for those ‘in care, no VL’ (box C). In order to estimate Community Viral Load as accurately as 
possible, local public health jurisdictions should implement programmatic activities to expand and 
routinize HIV testing [18] so that the proportion of ‘undiagnosed’ (box E) is as small as possible, 
and maximize linkage to and retention in care of HIV-diagnosed persons so that the proportion of 
‘diagnosed but not in care’ (box D) is as small as possible. In jurisdictions where (i) the percentage 
of persons that are in care but have missing viral loads and persons that are diagnosed but not in 
care (boxes C and D, respectively) when combined is less than 25% of persons, and in particular, if 
(ii) additional data relating to care and health status are available (such as history of antiretroviral 
therapy, insurance status, opportunistic infections, and engagement in care), techniques such as 
multiple imputation may be considered in modeling Community Viral Load for the total diagnosed 
population (in and out of care). However, the limitations of multiple imputation and the lack of 
additional data make calculation of Community Viral Load not feasible for most jurisdictions at this 
time. Methodologies for such analyses are an active area of research.  
In-Care Viral Load includes both the readily observable HIV viral loads of persons who have 
accessed the healthcare system, been diagnosed with HIV infection, and have viral load testing 
results reported to HIV surveillance (boxes A and B) and persons that may be in care, but as 
mentioned above, due to incomplete reporting or less frequent VL monitoring, do not have viral 
load data available (box C, Figure 2). Persons ‘in care, no VL’ are identified by HIV surveillance 
data as persons with CD4+ T-lymphocyte count or other test result but without any VL result. After 
refining surveillance data, persons that are in care but do not have a VL result should represent a 
small percentage of persons “in care” and may represent persons that are receiving health care but 
not HIV care, have declined HIV monitoring, or have inadequate VL monitoring. An example is 
persons not engaged in HIV care but who have received emergency department services in which a 
CD4+ T-lymphocyte count was obtained. Although the ‘in care, no VL’ group includes patients 
refusing HIV care for which they have the right, persons in this group may also represent missed 
opportunities to engage in HIV care. Because the U.S. HIV Treatment Guidelines recommend the 
ongoing monitoring of CD4+ T-lymphocyte and viral load, these persons identified by surveillance 
with only CD4+ T-lymphocyte counts are likely receiving suboptimal HIV care and their viral loads 
are likely not suppressed and may follow more closely the natural history of CD4+ T-lymphocyte 
count and viral load [19].  
In-Care Viral Load may be used as a quality of care indicator for the general population engaged in 
care of a jurisdiction. If measured over time, it should reflect access to healthcare, acceptance and 
adherence to antiretroviral therapy, and adequate clinical monitoring of VL. For a particular 
healthcare system (e.g., an HMO, a U.S. veterans cohort), In-Care Viral Load can be used as a 
rough proxy Measure of access to antiretrovirals, level of antiretroviral medication adherence, 
patient compliance with disease monitoring, and quality of care delivered to a patient population. 
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Importantly, data on CD4+ T-lymphocyte count and supplemental data on antiretroviral treatment 
for included cases can greatly aid the interpretation and understanding of In-Care Viral Load. 
Entities interested in estimating In-Care Viral Load should expand efforts to minimize the 
proportion of persons in care who have underreported or otherwise missing viral load in their 
medical records and, ultimately, in the HIV surveillance system. However, the limitations of 
imputation for ‘in care, no VL’ and the lack of additional data make calculation of In-Care Viral 
Load not feasible for most jurisdictions at this time. Methodologies for such analyses are an active 
area of research.  
Monitored Viral Load is limited to the readily observable HIV viral loads of persons who have 
been diagnosed with HIV infection, who are receiving HIV medical care and disease monitoring 
through viral load testing, and whose test results are reported to HIV surveillance (boxes A and B, 
Figure 2). This Measure excludes persons that may be in care, but as mentioned above for In-Care 
Viral Load, do not have viral load data available (box C) due to incomplete reporting or less 
frequent monitoring. As missing VL data for ‘in care, no VL’ become evident through improved 
surveillance data quality and adequate monitoring of HIV disease, this component measure will 
decrease in size, and the In-Care Viral Load Measure will approach the Monitored Viral Load 
Measure. After data refinement, the difference between the two surveillance Measures may be 
attributed to persons that may be refusing disease monitoring with VL testing and persons that are 
receiving inadequate VL monitoring. Monitored Viral Load may be used as a quality of care 
indicator for persons engaged in HIV care within a jurisdiction. If measured over time, it should 
reflect the combined access and adherence to antiretroviral therapy at a population-based level. For 
a particular healthcare system (e.g., an HMO, a U.S. veterans cohort), Monitored Viral Load can be 
used as a rough proxy Measure of access to antiretrovirals and level of antiretroviral medication 
adherence of a patient population.  
Jurisdictions may consider calculating a variety of measures to describe Monitored Viral Load, 
including measures of central tendency and dispersion. One approach to examining the quality of 
HIV care, antiretroviral treatment uptake, and adherence and engagement in care is to determine the 
percent of persons virologically suppressed, or the percent that are undetectable (lowercase m, 
measurements). Among persons that are receiving antiretroviral treatment, the proportion that 
achieves viral suppression is referred to as maximal virologic suppression [16] and has been 
endorsed as a quality of HIV care measure by various national groups. Additional measures are 
discussed in the Technical Guidance section. 
For jurisdictions with overlapping projects such as Test and Treat initiatives, Medical Monitoring 
Project (MMP), or other clinically oriented projects that capture use of antiretroviral medications, 
percent suppression is a useful population-based measure of the penetration of the U.S. HIV 
Treatment Guidelines. HIV care measures calculated from HIV surveillance and clinically collected 
data will help to evaluate suppression rates among different disproportionately affected populations 
as highlighted in the National HIV/AIDS Strategy.  
Summary 
It is challenging to estimate Population Viral Load, Community Viral Load, and In-Care Viral Load 
at this time. Jurisdictions able to address missing viral load data among diagnosed resident persons 
with HIV by using multiple imputation [9] have been able to calculate Community Viral Load as 
defined in this document. Those jurisdictions able to impute missing viral load data would also be 
able to calculate an In-Care Viral Load. For those jurisdictions that are unable to impute missing 





This section provides guidance on analytic decisions and methodologic considerations for 
conducting viral load (VL) analyses and calculating VL Measures using HIV surveillance data. 
Estimation of Community VL, In-Care VL and Monitored VL, as described in Establishing a 
Common Language, will be the focus of this section. Each subsection topic will include a 
description, recommendation, or discussion if no recommendation is provided, and an 
explanation that follows the recommendation.  
Selected standardized categorical VL measures are also defined so that comparisons across 
jurisdictions may be possible. These standardized measures and methodologic recommendations 
are enclosed within a grey box. An example of VL data to report is included in Figure 4 and a 
brief discussion of Population VL follows. Because of the variability in types of analyses, a 
checklist at the end of this section identifies key explanatory elements that should be described in 
the method section of any Community VL or related analysis.  
Getting started  
As described in Appendix B, Surveillance, a number of periodic, routine surveillance activities 
must occur to ensure HIV surveillance data are accurate and of sufficient quality. Those steps 
and others, which will be described in this section, provide the framework for Figure 3, Decision 
tree for conducting viral load analyses.  
Note: Geographic analyses may be conducted as a subset of Community VL/In-Care VL or a 
subset of Monitored VL. 
Inclusion criteria for cases 
Depending on the type of analysis an HIV jurisdiction plans to conduct, the case inclusion 
criteria may differ. For the purposes of standardization, however, the following criteria for case 
selection as part of a cross-sectional Community VL, In-Care VL, or Monitored VL analysis is 
recommended: 
Explanation: HIV-infected adults and adolescents may transmit HIV through sex and injection 
drug use. At the time of this writing, the latest full calendar year that could be examined is 2009, 
allowing for the minimum 12-months lag time for cases to be reported (i.e., using data reported 
through December 2010), data to be found and entered, etc. Using a calendar year and including  
 
Inclusion Criteria (for cross sectional review) 
Examine a single calendar year, allowing at least 12 months for data lag—2009 used as an 
example 
• Use data reported through December 2010  
• HIV-infected persons aged ≥13 years, alive on December 31, 2009, and diagnosed by 
December 31, 2009 or earlier 
 Interstate and intrastate deduplication conducted recently (within 6 mo) for 2009  
 Match to state vital registry and at least one National Death Registry through 2009, 
accounting for lag time of registry data 
• HIV surveillance sites may initially include only jurisdictional cases, but should make 























































persons alive at the end of that year is consistent with data requests from HRSA and most local 
HIV planners. For reporting cities within a state, those reporting jurisdictions will also need to 
conduct an intrastate deduplication process to determine which persons may have moved out of 
the jurisdiction but remain in the state. All states must participate in the interstate deduplication 
process. By the case inclusion criteria, HIV-infected persons who died during 2009 or earlier 
would be excluded. To keep track of those deaths, matching to state vital registry databases will 
help identify deaths among HIV-infected persons who died in state; matching to at least one 
national death registry (National Death Index or Social Security Death Index) is necessary to 
identify deaths that may have occurred out of state. Although each HIV surveillance jurisdiction 
has incentive to keep track of its jurisdictional cases, residential cases are more important to 
understanding current HIV transmission in a locality.  
Sample size 
The sample size needed to detect a 3-fold geometric mean (GM) difference* between mean viral 
loads depends on the desired power and standard deviation of the sample. Table 1a presents 
sample sizes needed with 80% power to detect a difference at the 0.5 level for various GM. The 
dark row lists the sample size needed to detect a difference of 3-fold in the GM; the sample size 
is the intersection of the row and column, standard deviation, S. The column of S=1.2 reflects the 
standard deviation observed in national VL data. 
Table 1a. Minimum sample size for detecting GM ratio of k with  = 0.05 and W = 0.8 
  S 
k 1 1.1 1.2 1.3 1.4 1.5 
1.5 399 483 574 674 782 897 
2 136 165 196 231 267 307 
2.5 78 94 112 132 153 176 
3 54 66 78 92 106 122 
3.5 42 51 60 71 82 94 
4 34 41 49 58 67 77 
5 25 31 36 43 50 57 
7 17 21 25 29 34 39 
10 12 15 18 21 24 28 
 = significance level 
W = power 
GM = geometric mean 
S = standard deviation; 1.2 is the standard deviation of national VL data 
                                                            
*  From the U.S. HIV Treatment Guidelines, Guidelines for the use of antiretroviral agents in HIV-infected adults 




Table 1b is the same as Table 1a except it uses power=90%. The statistical equations used for 
Tables 1a and 1b can be found in Appendix G.  
Table 1b. Minimum sample size for detecting GM ratio of k with  = 0.05 and W = 0.9 
  S 
k 1 1.1 1.2 1.3 1.4 1.5 
1.5 552 668 795 933 1083 1243 
2 189 229 272 319 370 425 
2.5 108 131 156 183 212 243 
3 75 91 108 127 147 169 
3.5 58 70 83 98 113 130 
4 47 57 68 80 93 106 
5 35 42 50 59 69 79 
7 24 29 35 41 47 54 
10 17 21 25 29 34 39 
 = significance level 
W = power 
GM = geometric mean 
S = standard deviation; 1.2 is the standard deviation of national VL data 
Explanation: Sample size considerations must be taken into account when choosing the cases or 
study population to examine. For example, Monitored VL among African American men and 
women may be of great interest to evaluate by a jurisdiction, but if the sample size is inadequate 
to meet the recommended case inclusion criterion, an alternate method may need to be used, 
such as combining multiple years of data. 
Jurisdictions may want to explore factors related to differences in means of viral loads, such as 
the difference in the proportion with undetectable or very low VL, which may be expressed as a 
categorical difference. 
Crude viral load data and differences in lower limits of detection 
With the advent of newer assays for quantifying HIV viral load, the lower limit of detection 
(LLD) of these assays has steadily decreased from <1000 copies/mL in the early 1990s to <400 
copies/mL in the early 2000s to <50 copies/mL or fewer in most recent years. Most persons that 
receive and adhere to antiretroviral therapy will have a viral load below the LLD, and a question 
arises how to handle their viral loads in the analyses.  
Explanation: The distribution of actual VL values below a test’s LLD is unknown. Factors that 
may influence the VL distribution in a jurisdiction include the regimen of and adherence to 
antiretroviral therapy among the cohort, sensitivity of assay used in measuring these otherwise 
We recommend that half of the LLD be used in the analyses of viral loads for persons who 
have VL below the limit of detection (whether numeric result provided or not) to approximate 
the likelihood of their actual viral load burden.  
Each jurisdiction will need to assess the standard deviation of their local VL data and then 
determine the appropriate sample size needed to assess VL. 
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undetectable VL results, and possibly the combination of patient demographics and clinical 
characteristics of HIV-infected persons at the time. Some researchers have used zero or the value 
LLD minus one as the VL value for undetectable results in VL analyses. We chose half the value 
of the LLD as a compromise and for its ease of use. As more data become available, it will be 
possible to more accurately establish a value for VL results currently classified as undetectable. 
Nevertheless, for our purposes of providing a uniform method that can be compared across sites 
or within a site over time, use of half LLD should be adequate. Consequently, when a viral load 
assay with LLD <50 copies/mL is used, undetectable viral load results should be replaced with 
25 copies/mL for analysis. 
When undertaking a calendar-time trend analysis, however, it may be necessary because of 
different viral load tests in use to truncate the lower limit of detection and possibly the upper 
limit of detection†. After examining local VL data by year, it should become apparent where 
those cut points are needed. As an example, if a jurisdiction had complete and refined data from 
2005–2009, it may be found that viral load tests with a LLD <400 copies/mL were in wide use in 
2005 and 2006, but then were replaced by a more sensitive test with LLD of 75 copies/mL by 
2009. For such an example, test results of undetectable, 400 copies/mL or less would be 
collapsed into a single group and given a VL value of 200 (half LLD) for each year, 2005 
through 2009. VL analyses for each year would then be conducted using this common LLD of 
400. If a single year, 2009, as a point in time analysis was planned, however, it would be 
appropriate to use 75 copies/mL as the LLD and use 37.5 as the value for analysis when results 
of ≤75 copies/mL or undetectable were reported. In either situation, the LLD or range of VL 
results used in analysis should be stated. 
Multiple imputation of missing viral load 
Although only 15 of 26 jurisdictions responded to an informal survey conducted among 
Workgroup members, most jurisdictions reported missing VL information for more than 30% of 
their cases [20]. VL results may be missing for persons not in care, in care but without VL, and 
for persons who have died or moved away as described in Appendix B, Table B1. This 
discussion of multiple imputation of missing viral load for calculating Community VL and In-
Care VL applies to data that have been refined after completing data management processes 
described in Appendix B, Surveillance. 
Explanation: Two groups of HIV-infected persons have, by surveillance definition, missing VL 
results—those “in care, no VL” and those “diagnosed but not in care” (boxes C and D, 
respectively, Figure 2). After data refinement, if the number of persons “in care, no VL” is small, 
jurisdictions may want to conduct follow-up to better characterize these persons. This 
information may help inform approaches for data imputation for this group, “in care, no VL.” 
Jurisdictions that routinely collect supplemental information—such as use of antiretroviral 
medications, engagement in care, insurance, co-morbidities—may wish to explore data 
imputation using published methods [9] that would enable them to calculate a Community VL or 
                                                            
†  Sites should assess their data and determine if an upper limit of detection is needed. Because of the recommended 
methods, providing a uniform upper limit of detection is not warranted in most circumstances. If, however, sites 
have a significant percentage of high VL results, use of an upper limit of detection may be prudent. 
We recommend that imputation of missing VL data only be attempted if <25% of cases are 
missing VL AND jurisdictions are collecting supplemental clinical data.  
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In-Care VL. However, jurisdictions should carefully weigh the benefits and limitations of 
multiple imputation before embarking on such analyses. 
Methods like multiple imputation that extrapolate from available surveillance VL data to the 
remainder of the population may not be appropriate for surveillance data. A fundamental 
requirement of imputation, that data are missing at random and that the distribution of values in 
the unknown group mirrors the distribution of values in the known, may not be satisfied. The 
fundamental problem for a “diagnosed case but not in care” identified from surveillance data 
(i.e., lacking VL data in a surveillance system that routinely receives fairly complete VL data 
from labs) is that the case is not in care or has moved out of jurisdiction. The viral load 
distribution of cases not in care cannot be modeled from the distribution of those that are in care. 
The Workgroup is not aware of any supplemental data available to the majority of surveillance 
jurisdictions at this time that could address this lack of information. 
Even if supplemental information is available to support randomness or similarity (these would 
likely derive from research samples also reflecting patients in care), there is no clear cut-off for 
how much information may be imputed (e.g., the recommendation of 75% as the minimum 
threshold for data completeness). The usefulness of supplemental data for “filling in the blanks” 
depends on the relevance, completeness, and accuracy of the data; it also depends on the 
homogeneity of the population that is being modeled. Jurisdictions are advised to consult with 
statisticians familiar with the methodology when planning analyses that involve imputation. 
Mean viral load 
The early VL and prevention studies have used median viral load as the summary analytic 
measure for community viral load; others have used the mean of the VL results. Because 
successful clinical use of antiretroviral therapy results in viral suppression, jurisdictions that have 
successfully engaged HIV-infected persons in care may have over 75% of such persons with 
undetectable VL; the median would be undetectable, so the mean was used. 
Explanation: The rationale for this logarithmic transformation is that it helps to normalize the 
distribution of viral load values and reduces the influence of outlying measurements for persons 
having extreme viremia (due to acute infection, advanced HIV disease, concurrent sexually 
transmitted infections, or random variability).‡ Since the interpretation of viral load 
measurements is often more intuitive on a linear scale, we recommend calculation of geometric 
mean (GM) for viral load. The GM is thus calculated through log transformation by averaging 
the log transformed values and transforming the average back to the original (linear) scale. The 
base used for the log transformation has no effect on the final GM estimate. However, using log 
base 10 has an advantage by its relationship to the value on the original scale; for example, a 
value of 2 on the log10 scale is 100 on the original scale, 3 corresponding to 1000, 4 
corresponding 10000, and so forth. 
While our recommendation for calculating the mean viral load is limited to Population VL, 
Community VL, In-Care VL, and Monitored VL, jurisdictions may wish to calculate a mean VL 
                                                            
‡  This is similar to using the median VL 
We recommend that calculation of Community VL and its related viral load Measures (see 
Figure 2) is performed after transformation of viral load results onto the logarithmic base 10 
scale, followed by calculation of the mean.  
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for a subpopulation. In addition, a geometric mean could be useful in combination with 
categorical VL measurements (see below). For example, the population can be described in 
terms of the fraction with undetectable or suppressed VLs and the (geometric) mean of the 
remaining population.  
Selection of viral load results for analysis 
Once the time frame for analysis is decided, the handling of VL values for individuals that may 
have more than one VL result needs to be considered. Depending on the type of analysis, 
jurisdictions may want to average the VL results for each individual and then take the mean of 
those average VLs to compute the Community VL, In-Care VL, or Monitored VL. For other 
analyses, it may be more appropriate to use the highest, lowest, or most recent VL result. (See 
Other viral load methods and analyses later in this section.) 
As part of the standard case inclusion criteria for a calendar year, the following VL should be 
selected for analysis: 
Explanation: The examination of a single VL result (most recent) is the least restrictive definition 
of ‘being in-care.’ Whereas other new measures or definitions of ‘in-care’ require at least two lab 
results within a specified timeframe of each other in a 12-months period, no such requirement is 
necessary for this standardized, point in time examination. 
The Community Viral Load Workgroup has developed and tested an Excel spreadsheet that 
allows for calculation of mean viral load, proportion suppressed, proportion undetectable, and a 
Z-test to identify a statistically significant difference between two mean viral loads. This 
spreadsheet accommodates small datasets. 
A generic SAS program that incorporates the methodologic guidelines and standards set forth in 
this document will also be available. The SAS code will be created so that large volumes of data 
from eHARS can be used for VL calculation by all HIV surveillance jurisdictions.  
Categorical measures of viral load 
Viral load results may be grouped into various clinically meaningful categories. Tracking VL 
categories for a population yearly (e.g., using histograms) may aid in the interpretation of 
changes in VL results in the population over time, concomitant with changes in proportion of 
patients receiving highly active antiretroviral therapy or adherence support, or due to other 
factors. 
We recommend use of three categorical VL measures: suppressed/not suppressed, 
undetectable, and high VL. 
Use the most recent VL result per person for analysis—this would be for specimens obtained 
in 2009 that are the closest to December 31. If there is no VL specimen for a case in 2009, 
that case would be excluded and would belong to either the “In care, no VL” or “Diagnosed 
but not in care” boxes of Figure 2 (boxes C and D, respectively). 
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Although the VL cut points that define each of these categories may not meet all needs, given the 
nature of ever evolving VL test technology, we have proposed definitions so that all HIV 
jurisdictions can report using standard definitions of these measures. The three standardized 
measures that are proposed are as follows: 
Explanation: A measurement that may be useful in describing the disease status of local PLWH 
is percentage of persons that have viral load below LLD or suppressed viral load, defined as 
VL ≤200 copies/mL by the latest U.S. HIV Treatment Guidelines [21]. Percentage of persons 
that have viral load suppression may serve as a rough proxy indicator of the combined access to 
and adherence to antiretroviral therapy in a given population.  
Explanation: This measure can only be assessed in jurisdictions where recent sensitive assays 
(LLD of 50 copies/mL or lower) are consistently used by laboratories. While this measure is 
most informative for a clinical setting among persons on antiretroviral therapy, it could also be 
applied to populations receiving care from a specific facility or across all persons in care using 
surveillance data.  
Explanation: To better characterize the spectrum of viral loads in the population, some 
jurisdictions may opt to quantify the proportion of VL results that are considered very high (i.e., 
>100,000 copies/mL), which may indicate high potential transmission risk for a group or the 
healthcare challenges facing a group in need of immediate antiretroviral therapy [21].  
Another potential categorical measure that jurisdictions may want to examine is the proportion of 
HIV-infected persons that meet a standardized definition of in-care—e.g., at least two lab results 
obtained within a calendar year that are at least 60 days apart. 
Categorical measures might be more informative than means and may also be more 
comprehensible to planners, evaluators, policy makers, and others. These measures provide the 
VL distribution and have the advantage of not implying a normal distribution of values (as 
means may be perceived by the public). The actual distribution of VL results in surveillance 
populations is highly skewed. A large proportion of the population has undetectable or very low 
values (e.g., <200 copies/mL), and the remainder of values are spread across a wide range. 
Distributions such as these are not well represented by a single measure, especially one that 
implies a normal distribution. Jurisdictions should examine their data to determine the local viral 
load distribution and the best measures to describe it, including outlier cutoff values, etc. Other 
measures are listed in Table 2. Such distributions can also be stratified by CD4+ T-lymphocyte 
count to reflect stage of illness and the U.S. HIV Treatment Guidelines recommendations on 
initiation of antiretroviral therapy. 
Report percentage ≤200 copies/mL as suppressed as a categorical VL measure. Conversely, 
the percentage >200 copies/mL may be reported as not suppressed. 
Report percentage ≤50 copies/mL as undetectable as a categorical VL measure. 




Address and residency 
For analyses that use address (geospatial analyses or linkage to Census geographic information 
on social determinants data), the current address, if available, should be used. Current address is 
also useful in establishing whether a jurisdictional case may have moved. While most 
jurisdictions use patient address from lab reporting, this information is useful only if the address 
is accurate. Patients with post office boxes or incomplete or inaccurate street addresses cannot be 
geocoded and placed with certainty on a map.  
A timeframe in which current address should be updated could not be agreed upon by the 
Workgroup. Any analyses including cases by residence or using geographic analyses should 
specify when addresses were updated and the percentage of cases that could not be geocoded 
with a high level of confidence. 
Population Viral Load 
The Technical Guidance section provides methodologic recommendations for calculating 
Community VL, In-Care VL, and Monitored VL. Although Population VL is the best Measure 
for assessing HIV transmission, information is not available for its calculation. However, a 
component VL measure that is of interest includes an estimation of the number of undiagnosed 
HIV-infected persons. A back-calculation method estimated that almost 250,000 HIV-infected 
persons are undiagnosed (21% of the total number of HIV-infected persons) in the United States 
[16]. Efforts are underway to also estimate the relative proportion of undiagnosed HIV-infected 
persons by state or metropolitan statistical area. These methods will be available to state health 
departments in 2011. 
VLs will vary greatly among undiagnosed persons, depending on how recently the person was 
infected. However, they may be assumed to not have suppressed VL.  
Other viral load methods and analyses 
Although this Guidance document suggests using one VL result (most recent) of possibly many 
VL results for a person and recommends a method for calculating VL Measures, viral loads may 
be analyzed differently. Table 2 includes different VL measures that have been calculated and 
reported. Each measure has particular strengths and uses. Appendix A lists the references 
associated with the VL analyses. 
The mean viral load provides an estimate of the average level of viral burden and is the most 
useful for comparing subpopulations and neighborhoods in a jurisdiction. Comparing mean of 
most recent and total VLs at the geographic level may reflect disparities in access to and use of 
antiretroviral medications by neighborhood. Comparing means among different subpopulations 
within a jurisdiction can highlight disparities. The total VL is a useful measure for looking at the 
combination of HIV prevalence and viremia among prevalent cases. 
Depending on the type of analysis that is being conducted, VL results other than the most recent 
may be appropriate to use. If the purpose of the analysis is to evaluate a new measure of quality 
of care, the researcher may choose to report the proportion of cases that were virologically 
suppressed for a calendar year; thus, cases with even a single VL result >200 copies/mL would 
not be considered suppressed for the year. If the focus of the analysis is on acute antiretroviral 
need and possible lapses of optimal antiretroviral use, then the proportion of cases that may have 
a single VL result >100,000 copies/mL may be used. Although we recommend the most recent 
(to December 31) VL within a calendar year be used to calculate a VL Measure that is a more 
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“current” snapshot, researchers may also want to use the mean of serial VL results obtained 
throughout the year for a person and then calculate the overall mean VL among all persons in a 
group for the year. Again, this document is not meant to be a comprehensive list of all possible 
VL analyses and measures but to point out ones in use and to recommend a common method for 
calculating VL Measures and reporting of component and a limited number of categorical VL 
measures. 
Summary for data reporting—see Checklist on page 20 
For each type of population-based analysis, Population VL, Community VL, In-Care VL, and 
Monitored VL, the study population should be described and its size should be reported. The size 
and relative percentage of each of the component VL measures (boxes A–E), as shown in Figure 




Table 2. Types of viral load (VL) analyses and measures† 
VL analysis/measure How to calculate What it tells you 
Mean of most recent VL* Determine the most recent VL for 
each case, total the values of those 
VLs, and divide by the number of 
cases with a VL. 
The average number of virus 
particles in a population; can be 
influenced by large outliers; useful 
for comparisons between sub-
populations (e.g., disparities) 
Mean of most recent log 
transformed VL* 
Log transform the most recent VL 
for each case, average the log 
transformed values, total the average 
values, and divide by the number of 
cases with a VL. 
The log transformation will 
provide a stable estimate by 
reducing the influence of outliers; 
tightens the association of trend 
between decline in CVL and new 
diagnoses 
Mean of mean VL* Determine the mean VLs for each 
case, total the values of those mean 
VLs, and divide by the number of 
cases with a VL. 
Provides an average of the average 
number of virus particles per case; 
this may reflect a greater influence 
of those individuals with multiple 
measurements and those who were 
started on ART and trended 
towards suppression within 1 year 
Total VL Sum of VLs for all cases. The number of virus particles in 
the population who have a VL; 
affected by the number of cases; 
reflects both prevalence of HIV 




The numerator is the number of 
cases whose most recent VL was 
suppressed; the denominator is the 
number of cases with a VL. 
Maximal Virologic Suppression, or 
the percent virologically 
suppressed reflects ART uptake, 
adherence, and effectiveness in 
clinical settings; a quality of HIV 
care measure; in jurisdictions 
offering universal treatment, an 
important marker of uptake of 
universal ART guidelines  
ART, antiretroviral treatment. 
† Time needs to be defined for each calculation, usually a 12-month period. Pooling over a few years can increase 
VL completeness but is harder to interpret.  
* The denominator includes all viral load results, including undetectable viral load. 
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It may not be possible for many jurisdictions, at this time, to calculate a Community VL or In-
Care VL estimate because of an inability to estimate VLs for persons “Diagnosed but not in 
care” or “In care, no VL.” 
Explanation: In addition to standard component and categorical measures, jurisdictions may also 
choose to report alternate categorical VL measures that use other VL cut points that are 
meaningful to their area. 
Examples for Data Reporting (bottom up) 
 
Jurisdictions should report: 1) the component VL measures—e.g., percentage of persons 
“Diagnosed but not in care” in addition to the percentage, “In care and with undetectable* 
VL,” “In care with detectable VL,” and “In-care, no VL” when conducting In-Care VL 
Measurements; and 2) on categorical VL measures to describe the population that is in care 
and being monitored such as the percentage of persons with suppressed (i.e., ≤200 
copies/mL), the percentage with high viral loads (i.e., >100,000 copies/mL), and the 






Checklist§: Items to include when reporting on Community VL or related analyses  
Introduction 
  Describe the rationale for the analyses and specific objectives; e.g., estimating HIV transmission potential of the population, 
assessing quality of care indicator, monitoring the outcomes of programmatic interventions 
Methods 
Analysis design and measurements 
  Describe key elements of analysis design (cross-sectional, longitudinal), including relevant dates  
  Describe data sources and method for selection of persons and viral load measurements  
(e.g., allowing ≥1 year reporting lag in data analyzed; Persons alive as of when? Handling of VLs for those who died in the 
year? Resident vs jurisdictional cases? Timeframe when residency last assessed)  
  Describe any data quality assurance processes and when conducted (matching to local vital statistics data, National Death 
Index, or Social Security Death Index, determination of patient residency through laboratory data, Routine Interstate 
Deduplication Review, intrastate review, etc.; see the Technical Guidance section) 
  Present n (%) of cases with missing viral load data or excluded for any reason (consider a flow diagram) 
  Define all outcomes and how computed; e.g., geometric mean of VLs, percentage of VLs <200 copies/mL, locally-defined VL 
categories, etc. 
  Define other variables; e.g., which address/ZIP Code used for geospatial analyses; how current? present n (%) of addresses that 
could not be geocoded 
  Specify what the VL lower limit of detection (LLD) was and how they were handled in the analyses (see Technical Guidance) 
  Justify categories chosen for categorical independent or outcome variables, as appropriate 
Analyses 
  Describe all statistical methods (e.g., tests for trend; accounting for multiple observations per patient; data imputation and 
variables used in imputation, if used; geospatial analyses; multivariable modeling) 
  Describe sample size calculations if used (e.g., for comparison of VL Measures between 2 patient subgroups) 
  Describe any methods of adjustment for confounders (e.g., standardization, multivariable modeling) 
  Describe any efforts to address potential sources of bias due to missing data, sensitivity analyses (e.g., imputation). 
Results 
  Give characteristics of the study population and univariate summaries of outcome measures 
  Report variability (e.g., standard deviation) and precision (e.g., 95% confidence intervals) around estimates 
  Present results from adjusted analyses, controlling for potential confounders 
Discussion 
  Discuss limitations of the analyses, taking into account potential sources of bias or imprecision; discuss both direction and 
likely magnitude of the bias (e.g., under or over estimation of Community VL) 
 Interpret findings in the context of prior analyses—highlight differences and similarities 
 Discuss generalizability of the results 
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Title Author Venue Source Population VL analysis Method/notes Data presented 
Longitudinal community plasma 
HIV-1 RNA concentrations & 
incidence of HIV-1 among IDUs: a 









Correlated 6 mo CVL & 
incidence (& % ART); 
modeled time to HIV(+); 
covariates: 6 mo CVL and 
IDU risk  
Geographic, demographic, and 








Mean of the 
means of 
individual VLs in 
period 
K Wallis Differences in CVL by 
demographic, risk 
category, clinical status, 
CVL geography 
Population-level assessment of the 
geographic, demographic, and health 
status correlates of virologic 
suppression among all San 





Poster PLWHA w 
<350 CD4 
Mean VL (75 & 
400 cut points) 
Wald adj OR + GEE Two models, outcome1: 
VL <75 and 
outcome2: VL <400; 
covariates: demographics, 
clinical, access to care 
CVL: Geographic, clinical and risk-
related disparities in a novel 
population-based biomarker of HIV 







Mean recent VL K Wallis; floor: ≤75 Differences in CVL by 
demographics, risk 
category, clinical status, 
CVL geography 
Decreases in CVL are accompanied 
by reductions in new HIV infections 







Mean + total 
recent VL, % VL 
suppressed 
K Wallis, Poisson 
regression; floor: ≤75, 26% 
missing VL imputed 
Test & Treat parameters, 
'04 & '08; modeled new 
dx/incidence; total CVL, 
mean CVL, and % VL 
suppressed 
Association of highly active 
antiretroviral therapy coverage, 
population viral load & yearly new 
HIV dx in British Columbia, Canada: 









Poisson log-linear; floor: 
≤500, ceiling: ≥100K  
Correlated HAART and 
incid, 3 time periods; 
modeled new dx; 
covariates: VL, HAART 
use, yr 
Decreases in community viral load 
are accompanied by reductions in 







Mean + total 
recent VL, % VL 
suppressed 
K Wallis, Poisson 
regression; floor: ≤75, 26% 
missing VL imputed 
Modeled new 
dx/incidence; examined 
total CVL, mean CVL, and 
% VL suppressed 
Predictors for high HIV viral load 
(VL) among persons with HIV in Los 
Angeles County using lab 





Abstract PLWHA w 
VL, 4/06–
10/09 
High VL (>10K) Mixed model Modeled high VL; 
covariates: demographics, 
SES, and behavioral 
factors 
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Title Author Venue Source Population VL analysis Method/notes Data presented 
Decline in community viral load is 
strongly associated with declining 





Poster cohort IDUs Log of mean of 
year's VLs 
Poisson regression; closed 
community 
11 yr trend: CVL, % ART, 
HIV incid, and % IDU; 
modeled IRRs x 3 
intervals; covariates: risk 
Trends in HIV viral load among 






Abstract HIV(+) in 
care 
Median log VL, 
% VL suppressed 
Floor: ≤500 (2.7log); 
Kruskal-Wallis; Clinical 
multisite study 
11 yr trend: annual VL, 
% VL suppressed by ART, 
race, risk group 
Use of community viral load as 
population-based biomarker of 





Poster PLWHA dx 
2004–08 
Mean + total most 
recent VL over 5 
yrs 
52% missing VL Trend mean and total CVL 
and new dx, Q6 mo x 5yr; 
mean CVL by risk; mean 
and total CVL by district 
Factors associated with persistent 






Poster PLWHA ≥12 
yo & 2 VLs 
≥2 wks 
Persistent high 
VL (>100K x 2 
cons VLs) 




suppressed vs. persistent 
VL 
Disparities in community viral load 





Poster PLWHA ≥13 
yo 2007& 
1VL '08 
Mean VL of 
detectable VL, 
% VL suppressed 
K Wallis, Jonckheere-
Terpstra; 36% missing VL, 
floor ≤400 
Mean detectable and % VL 
suppressed by risk; 3 yr 
trend % supp; geogr % 
supp, mean det VL, etc. 
Success of Test & Treat in San 
Francisco: reduced time to virologic 
suppression, decreased CVL and 





Poster PLWHA dx 
2004–09 
Yearly mean 
recent, min and 
max VL; log 
mean recent 
Poisson regression Time to ART, % VL 
suppressed by dx yr; 
% supp @ 6 and 12 mo by 
dx yr; modeled new dx; 
covariates: min, max, 
recent VL, year 
Venue: Journal names are underlined; scientific meetings include CROI (Conference on Retroviruses and Opportunistic Infections), IDSA (Infectious Disease Society of 
America), APHA (American Public Health Association). 
Source: Article refers to a scientific publication; PP is an oral presentation at a scientific meeting; abstract is a short description of study and findings submitted to a 
meeting; poster is a more detailed paper presentation at a scientific meeting. 
* As of May 2011 
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Public Health Surveillance 
Surveillance is the foundation of public health. It involves the ongoing, systematic collection, 
analysis, interpretation, and dissemination of data used by public health to reduce morbidity and 
mortality and to improve health [1]. Each surveillance system has a number of attributes that 
contributes to its overall effectiveness. These attributes include: simplicity, flexibility, data 
quality, acceptability, sensitivity, predictive value positive, representativeness, completeness, 
timeliness, and stability. To ensure ongoing improvement in data quality, efficiency, and 
usefulness, each surveillance system should be periodically evaluated. 
All CDC data originate locally. These data represent a commitment and collaboration between 
states or jurisdictions and CDC to collect data deemed to be the most vital in fulfilling local and 
national public health missions. CDC works with local reporting jurisdictions and the Council of 
State and Territorial Epidemiologists (CSTE) to establish model language and uniformity in state 
reporting regulations and standardization of data collected for surveillance. CDC works with 
state and local public health counterparts to decide on national data quality standards, policies, 
and procedures that can be used to meet surveillance data quality standards. 
HIV Surveillance 
HIV surveillance includes 65 reporting jurisdictions that represent the 50 states, District of 
Columbia, 6 cities and 8 U.S. dependent areas. Collectively, these 65 jurisdictions comprise 
national HIV surveillance data that allows for the enumeration and description of reported new 
diagnoses of HIV-infected persons, known or prevalent HIV-infected persons, and deaths among 
HIV-infected persons since the beginning of the U.S. epidemic in the early 1980s. National HIV 
case surveillance data includes all persons diagnosed with HIV and can be used as a sampling 
frame by other programs to establish representative samples for study or surveillance. 
State and local surveillance staff identify most HIV-infected persons by codified regulations that 
require healthcare providers (e.g., physicians, hospitals, clinics) and laboratories to report 
persons with lab test results diagnostic of HIV infection. HIV surveillance data are collected and 
entered into a standard database. The current HIV surveillance data system, eHARS, is a 
complex, relational database that collects sentinel HIV disease information through a document-
based process. Cases are reported to CDC without identifying information. 
As HIV disease and its treatment have evolved, so has HIV surveillance. HIV antiretroviral 
medications have greatly extended the lifespan of HIV-infected persons, transforming an acute, 
life-limiting disease into a more manageable chronic disease. Correspondingly, the role of public 
health surveillance data has evolved from describing persons diagnosed with HIV to assessing 
the course of the disease throughout their life, and their crucial linkage to and retention in care 
following diagnosis (see Figure B1).  
                                                            
1 CDC. Updated guidelines for evaluating public health surveillance systems: recommendations from the guidelines working group. MMWR 
2001;50(RR-13):1–36. 
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U.S. HIV Treatment Guidelines [2] recommends periodic laboratory testing of HIV-infected 
persons that are in care. From the surveillance system perspective, serial, periodic laboratory test 
results are a marker of ongoing utilization of, and access to, healthcare among HIV-infected 
persons. Recognizing the importance of lab data, states have bolstered their ability to collect 
these data by means of legislation requiring the reporting of CD4+ T-lymphocyte counts and 
plasma HIV viral load test results [3]. 
Because resources for HIV care and prevention are often determined by the person’s place of 
residence at the time of HIV and AIDS diagnosis, address is collected for these sentinel events 
and maintained by the local jurisdiction. As HIV-infected persons live longer, however, persons 
may move from one jurisdiction to another. Locally, information from lab reports can be used to 
update current patient address and identify in-migration of persons with HIV. To help account 
for in- and out-migration of HIV-infected persons and maintain accurate case counts, 
jurisdictions and states participate in CDC’s intra- and interstate deduplication processes. Cases 
with the same Soundex and selected demographic factors are referred back to the reporting areas 
to work out case “ownership” and surveillance responsibility. The reconciliation of such cases 
helps avoid overcounting and ensures accuracy of local and national estimates. Similarly, HIV-
infected persons may die out of state, so jurisdictions are provided the resources and encouraged 
to match their case registry not only against their state or local vital statistics registry data but 
                                                            
2 Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and 
adolescents. Department of Health and Human Services. January 10, 2011;1–166. 
3
 CDC. Reported CD4+ T-lymphocyte and viral load results for adults and adolescents with HIV infection—37 states, 2005–2007. HIV 
Surveillance Supplemental Report 2010;16(1). Table 8. Available at: 
http://www.cdc.gov/hiv/topics/surveillance/resources/reports/index.htm#supplemental. Published March 2011. Accessed April 27, 2011. 
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also against at least one national death registry [4] to ensure an accurate count of the number of 
people living with HIV disease in their jurisdiction. 
While accurate case counts are important to understand disease burden and where HIV-infected 
persons seek medical care is important for resource allocation, it is equally important to 
understand where and how new cases arise for targeted prevention efforts. Jurisdictional 
boundaries and residency do not predict where healthcare is sought or risk-seeking behaviors 
occur. For example, persons may cross into an adjacent state to receive health services or engage 
in high-risk behaviors in a neighboring jurisdiction. Some states have developed lab reporting 
regulations based on the patient’s residence and patient’s place of care to accurately describe 
care patterns. As part of understanding HIV transmission, surveillance areas with residents that 
cross state lines to engage in high-risk HIV behaviors should take this into consideration when 
conducting any assessment of HIV transmission potential for their residents. 
Assessing those in care 
In general, HIV surveillance relies on reported lab test (i.e., CD4+ T-lymphocyte count or viral 
load) results as a marker of persons receiving health care and thus being “in care.” While it may 
be possible to identify HIV-infected persons who are receiving care but lacking lab test results, 
such as persons identified from linking to Ryan White Care AIDS Drug Assistance Program 
databases, such cases can be followed-up to address the reasons for missing lab results. To 
determine whether someone was linked to and retained in ongoing HIV healthcare, serial lab 
results over an extended period would need to be observed in surveillance data. 
A limited number of HIV jurisdictions are able to conduct ongoing medical chart review of HIV-
infected persons that reside in their jurisdiction. Those jurisdictions have collected supplemental 
data that are not routinely collected as part of HIV surveillance, such as engagement in care, 
insurance, and use and type of antiretroviral medications. Other jurisdictions have been funded to 
participate in special surveillance/prevention activities and, as such, may also be conducting 
ongoing medical chart reviews and collecting similar type of supplemental data. 
States annually estimate the proportion of HIV-infected persons living in their state that are in 
and out of care. Some HIV reporting jurisdictions may report for their jurisdictional cases, not 
residential cases, because they are more likely to have complete information for their 
jurisdictional cases [5]. 
Viral load test results 
To ensure that all (detectable and undetectable) viral load results are received by HIV 
surveillance, jurisdictions must expend great time and resources. As a first step, state public 
health reporting laws or regulations provide the authority for State Health Departments to receive 
such information from laboratories. It may be necessary to include language that specifies that all 
(detectable and undetectable) HIV viral load results are reportable. This type of policy lays the 
foundation for receiving viral load results but cannot account for the personal interaction needed 
                                                            
4 The National Death and Social Security Death Indexes are both national death registries. The Social Security Death Index requires about one 
year for death data to be complete; the National Death Index’s lag time is about two years. An out-of-state death may provide the first piece of 
evidence that a person moved out of state. Although matching to a national death registry may help identify whether a person has died out of 
state, it does not help with HIV-infected persons who may return to their country of birth and then subsequently die. The magnitude of this 
problem is not known. This miscounting may contribute to an overestimation of some racial/ethnic groups that are considered not in care and 
an underestimate of some race/ethnicity-specific HIV-mortality rates. 
5  See the HRSA section that follows for explanation of jurisdictional versus residential case. 
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in establishing relationships with laboratories for reporting and then ongoing work to ensure 
continued reporting. The magnitude of this can be appreciated by the fact that some jurisdictions 
have over 80 laboratories that report viral load results [6].  
The volume of viral load reporting is large and is likely to increase. U.S. HIV Treatment 
Guidelines recommend periodic assessments among persons that are on antiretroviral therapy or 
among persons whose HIV disease is being monitored, and the number of persons living with 
HIV is increasing. It is not uncommon for a laboratory to cease VL reporting for a short period 
as new laboratory staff are hired or veteran laboratory staff take vacations. To identify such 
lapses in reporting, HIV surveillance jurisdictions monitor laboratories for their volume of 
reporting over time.  
The complete absence of any lab test result (CD4+ T-lymphocyte count or viral load) may 
suggest the person is not in care, moved away, is receiving care out of jurisdiction, or died, or 
there is a significant reporting issue (see Table B1). There are some instances, however, where 
an HIV-infected person resides and receives care within an HIV reporting jurisdiction but no 
medical care information is shared with HIV surveillance. There are a limited number of federal 
and private facilities that do not share or allow HIV surveillance staff to have access to medical 
records of persons being cared for by the facility. Efforts to address these barriers are underway 
with some facilities. 
As technology has advanced, laboratories are moving toward reporting lab results electronically, 
but many laboratories still do not have this capability. Some HIV reporting jurisdictions have a 
backlog of paper lab results, and some jurisdictions with early electronic lab reporting have 
maintained electronic HIV lab reports in a separate database apart from eHARS. Viral load 
results reported on paper that have not been entered into eHARS are not available for analysis. 
Separately stored electronic lab files that have not been entered into eHARS may also not be 
accessible for analytic purposes.  
The extent of missing lab results is best described from a recent survey of selected HIV reporting 
jurisdictions. Of the 15 jurisdictions that responded, 26–89% of persons living with HIV and 
reported to surveillance were missing a viral load result [6]. The large range of missing viral 
load results may be attributable to many factors as described in Table B1. 
The issue of jurisdictional versus residential case status has some implications for missing lab 
results. Persons diagnosed in one jurisdiction, by convention, remain in the database as a case in 
that jurisdiction even if the person moves across the country and receives care in their new home 
state. The recommended procedure for each HIV reporting area is to enter all lab results into 
their HIV database, regardless of jurisdictional or residential case status. After all jurisdictions 
upload their data to CDC, it may be possible to link lab results to jurisdictional cases that have 
moved; at this time, there is no mechanism that allows for sharing this information with local 
jurisdictions by CDC or between local jurisdictions directly. Early in the epidemic, when HIV 
diagnosis was often shortly followed by death, describing jurisdictional cases was reasonable. 
Today, with effective antiretroviral treatment available and the impetus to look more closely at 
transmission and prevention of new HIV infections, residential cases may also be an important 
population to surveil. 
                                                            
6  Community Viral Load Workgroup Survey, conducted January–February 2011 among the 26 participating Workgroup jurisdictions. 
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Table B1. Circumstances of missing viral load (VL) results and strategies for addressing 
Issue Strategy 
 State laws/regulations are not in place for 
laboratories to report all VL results  
 Detectable VL results may be used for a subset 
of VL analyses (see Figure 4b) 
Amend state regulations (see Appendix C, state-
specific status of reporting laws for all VL results). 
Although jurisdiction may be able to conduct limited 
analyses, they should strive to collect all VL results, 
using strategy listed above. 
 Not all laboratories that should be reporting VL 
results are reporting 
 May be limited to a period, such as during 
holiday season when staff coverage changes 
Get to know your local laboratories and establish 
relationship for reporting. 
Monitor the reporting by laboratory each month to 
ensure ongoing reporting. 
 Private or federal hospital/clinic labs do not report 
HIV lab results to state or allow surveillance staff 
access to medical records (varies by state or 
jurisdiction) 
Establish working relationship with local institutions; 
this may require federal assistance. 
 Neighboring HIV jurisdiction not sharing lab 
results with the jurisdiction in which the case 
resides (e.g., resident of State A receives HIV care 
in State B, State B receives all lab results from 
clinic in State B, but State B does not share those 
lab results with State A) 
Option 1: State A changes language of its lab 
reporting regulations to facilitate receiving its 
residents’ lab results. 
Option 2: Develop mechanism for data sharing. 
 There is evidence that HIV-infected persons are in 
care but VL results are missing (e.g., CD4 results 
but no VLs) 
Some investigation needed to determine reason for 
missing VLs; e.g., lab not sending VLs, etc. 
 HIV-infected person may have died  Jurisdictions should conduct annual data linkage to 
registries with death information, such as their state 
vital statistics database, and at least one national 
registry, such as the Social Security Death Index or 
National Death Index. 
 HIV-infected person may have moved out of 
jurisdiction 
Participate in CDC’s intra-and interstate case 
deduplication processes.  
 Not all VL results have made it into the 
surveillance data system (e.g., results reside on 
paper or in a supplementary database) 
Obtain resources to enter backlog of paper lab reports 
and continue with real-time entry; increase electronic 
reporting from labs; request CDC assistance to 
implement import into eHARS.  
 HIV-infected person is not engaged in ongoing 
care for his/her HIV disease (may be by choice or 
influenced by other social/mental health issues; 
other reasons, see Strategy) 
Partner with other public health colleagues and 
community-based organizations to determine reasons 
for not being engaged in care and, if possible, link to 
ongoing care. 
HRSA 
The Health Resources and Services Administration [7], HRSA, is one of several agencies, 
including CDC and NIH, under the leadership of U.S. Department of Health and Human 
Services. HRSA is responsible for improving access to health care services for people who are 
uninsured, isolated, or medically vulnerable.  
                                                            
7 HRSA web pages accessed on 29 April 2011 include: http://www.hrsa.gov/about/index.html, http://hab.hrsa.gov/tools/needs/NAGSecII.htm, 
http://hab.hrsa.gov/tools/HIVoutreach/HIVoutreach2.htm. 
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Since the early 1990s, the Ryan White HIV/AIDS Program has provided an array of HIV-related 
and health care services to help vulnerable HIV-infected persons manage their disease. Based on 
the numbers of persons infected with HIV, service needs among these persons, local resources 
available, and an assessment of unmet need and service gaps, HRSA provides states with funding 
to bridge these gaps. Medical care and antiretroviral medications (through the AIDS Drug 
Assistance Program) are just two services that HRSA funds through and in partnership with 
states. 
Each year, jurisdictions provide an epidemiologic description of HIV-infected persons to 
HRSA’s HIV/AIDS Bureau. Most of the data used to describe the epidemic in a jurisdiction 
originates from HIV surveillance, so it is important to try to harmonize terms and processes that 
meet both HRSA and CDC needs. 
Definitions and terms 
• Persons living with HIV (with and without AIDS) in a jurisdiction.  
 HIV surveillance would refer to these individuals as resident cases, which is distinct from 
jurisdictional cases. HIV surveillance case “ownership” is limited to jurisdictional cases that are 
residents at diagnosis. 
• Persons with unmet need are diagnosed with HIV infection but not in care for a defined 12-
month period [8]. 
 HIV surveillance uses lab test results (CD4+ T-lymphocyte count or viral load) as a marker for 
being in care. Those persons without a lab result for 12 months or greater would be considered 
not in care (or out of care). HRSA includes lab results and receipt of antiretroviral medications 
within a 12-month period as markers of being in care. 
• Persons “in care” are receiving primary healthcare for their HIV disease. This care should be 
consistent with the U.S. HIV Treatment Guidelines [2].  
 HIV surveillance uses lab test results as a marker for being in-care. While ongoing evidence of 
laboratory testing is strongly suggestive of ongoing encounters with the healthcare system, the 
quality and appropriateness of these medical encounters cannot be fully assessed with routine 
HIV surveillance data. For most surveillance jurisdictions, with geographically dispersed cases 
and varying health facility-specific rules and policies, costs are prohibitive to collect detailed 
medical care information. Collecting this type of medical encounter information is possible for 
circumscribed populations of HIV-infected persons and is part of the CDC’s Medical Monitoring 
Project (MMP), which includes a representative sample of HIV-infected persons who are engaged 
in HIV care. 
• HIV-infected persons are retained in care as assessed by at least two clinical visits in a year 
that are at least 60 days apart [9].  
 HIV surveillance uses lab results as a marker for being in-care. Based on the temporal distribution 
of the collection date for each lab test, it is possible to assess whether two medical encounters 
occurred within a calendar year, spaced at least 60 days apart. It would be difficult, however, for 
surveillance data to determine with certainty if the lab tests were part of the same continuous care 
                                                            
8  Douglas Morgan and Emily McKay. Estimating and assessing unmet needs; presented July 14 and 15, 2009 at CDC’s HIV Surveillance 
Workshop, Atlanta, Georgia. 
9  Horberg MA, Aberg JA, Cheever LW, Renner P, Kaleba EO, Asch SM. Development of national and multiagency HIV care quality measures. 
Clin Infect Dis 2010;51:732–738. 
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or might represent fragmented care as, for example, one test may be ordered by an HIV 
healthcare provider and another test ordered by an emergency department physician. 
• Persons in care that begin antiretroviral treatment achieve virologic suppression after 6 month 
[9] 
 HIV surveillance can provide a rough proxy assessment of reporting the proportion of persons in 
care that have viral load results ≤200 copies/mL for a calendar year. Because antiretroviral 
medication use and initiation is not collected by HIV case surveillance, this type of clinical 
measure is best addressed by MMP.  
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Viral load reporting by HIV surveillance reporting area as of April 2011— 
50 states, funded cities, District of Columbia, and U.S. dependent areas 
  Viral load 
State/Area   
Reporting 
required Reportable levela  
When all VLs 
became availableb 
Alabama  No — — 
Alaska   Yes All results Feb 1999 
American Samoa  No — — 
Arizona   Yes Detectable — 
Arkansas  Yes All results Jan 2005 
California   Yes All results Apr 2006 
Chicago  Yes All results Jan 2006 
Colorado  Yes All results Apr 2010 
Connecticut   Yes All results Jan 2006 
Delaware  Yes All results July 2001 
District of Columbia   Yes All results June 2007 
Florida  Yes All results Nov 2006 
Georgia   Yes All results Dec 2003 
Guam  Yes All results May 2009 
Hawaii  Yes All results Mar 2008 
Houston  Yes All results Jan 2010 
Idaho   Yes Detectable — 
Illinois  Yes All results Jan 2006 
Indiana   Yes All results Sep 2000 
Iowa  Yes All results Jan 2005 
Kansas   Yes Detectable — 
Kentucky  Yes Detectable — 
Los Angeles  Yes All results Apr 2006 
Louisiana   Yes All results Feb 1999 
Maine  Yes All results Apr 2008 
Maryland   Yes All results Apr 2007 
Marshall Islands  No — — 
Massachusetts  No — — 
Michigan   Yes All results Apr 2005 
Micronesia  No — — 
Minnesota  Yes Detectable — 
Mississippi   Yes All results Jan 1996 
Missouri  Yes All results June 2000 
Montana   Yes Detectable — 
Nebraska  Yes All results Jan 2001 
Nevada   Yes Detectable — 
New Hampshire  Yes All results June 2008 
New Jersey   Yes All results Jan 2000 
New Mexico  Yes All results Jan 1998 
New York City  Yes All results June 2005 
New York   Yes All results June 2005 
North Carolina  Yes Detectable — 
North Dakota   Yes All results Aug 2002 
Ohio  Yes Detectable — 
Oklahoma   Yes All results June 2007 
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  Viral load 
State/Area   
Reporting 
required 
Reportable levela  
When all VLs 
became availableb 
Oregon  Yes All results Aug 2006 
Palau  No — — 
Pennsylvania   Yes Detectable — 
Philadelphia  Yes Detectable — 
Puerto Rico  Yes All results Jan 2003 
Rhode Island   Yes Detectable — 
San Francisco  Yes All results Apr 2006 
South Carolina  Yes All results Jan 2004 
South Dakota   No — — 
Tennessee  Yes Detectable — 
Texas   Yes All results Jan 2010 
Utah  Yes All results Sep 1999 
Vermont   Yes All results Oct 2005 
Virgin Islands, U.S.  Yes Detectable — 
Virginia   Yes All results May 2007 
Washington  Yes All results Sep 2006 
West Virginia   Yes All results July 1999 
Wisconsin  Yes All results Jan 2011 
Wyoming   Yes All results Jan 2000 
a 
Level at which viral load reporting is required by state laws, regulations or statutes. All results include undetectable and detectable viral load test 
results. 
b 
For some states this is the time when the statute took effect; for other states, because of the breadth and lack of specificity of their reporting 
regulation, this is the period when they started to receive all VL results 
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U.S. HIV Treatment Guidelines 
The most recent update of Guidelines for the Use of Antiviral Agents in HIV-1–Infected Adults 
and Adolescents was released January 2011 [2] (hereafter referred to as the U.S. HIV Treatment 
Guidelines). The U.S. HIV Treatment Guidelines describe in detail the recommended clinical 
management of persons infected with HIV and from this and other work, HIV quality of care 
measures have been developed [8]. The focus of this section is on laboratory monitoring that is 
part of clinical management because lab data are actively pursued as part of HIV surveillance. 
As part of monitoring HIV disease progression and response to antiretroviral medications, 
monitoring of CD4+ T-lymphocyte counts and plasma HIV RNA concentration (viral load) have 
been recommended. Both tests should be ordered when an HIV-infected person enters care, at 
antiretroviral treatment initiation, every 3–6 months until clinically stable, and when clinically 
indicated. Because viral load is the most important indicator of antiretroviral treatment response, 
more frequent viral load monitoring may be performed when a treatment regimen is changed. At 
a minimum, one would expect at least 1–2 viral load measurements over the course of a year in 
which a person is engaged in HIV care. 
Tests that measure viral load have become more sensitive over time. Older viral load tests’ lower 
limit of detection was 1000 copies/mL, but some tests today can detect and quantitate as few as 
20 copies/mL. A viral load of 250 copies/mL may have been interpreted as undetectable using 
the older test but detectable using the most sensitive test available today. Across a jurisdiction, 
different viral load tests with varying levels of test sensitivity may be in use at the same time. 
Also, because there is some variability in viral load results at low levels, the U.S. HIV Treatment 
Guidelines adopted “viral load >200 copies/mL as indicative of virologic failure” [2]. For an 
individual, the minimal change in viral load that is considered significant is a 3-fold or a 0.5 
log10 copies/mL change. 
Antiretroviral treatment initiation, for the most part, is guided by CD4+ T-lymphocyte counts. 
One instance, however, in which viral load levels are used for treatment is when “rapid 
initiation of treatment is recommended when viral load is high, i.e., >100,000 copies/mL” 
[2]. 
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National HIV/AIDS Strategy 
In July 2010, the White House released the National HIV/AIDS Strategy [10]. The document 
included three primary goals: 1) reducing the number of people who become infected with HIV; 
2) increasing access to care and improving health outcomes for people living with HIV; and 
3) reducing HIV-related health disparities.  
The Strategy defines in its “Reducing HIV-Related Disparities and Health Inequities” chapter the 
following actions related to community viral load: 
 Step 1.1  Ensure that high-risk groups have access to regular viral load and CD4 tests. 
 Step 2.2  Ensure that all high prevalence localities are able to collect data necessary to 
calculate community viral load, measure the viral load in specific communities, and 
reduce the viral load in those communities where HIV incidence is high. 
The Federal Implementation Plan [11], a companion document to the National HIV/AIDS 
Strategy, lists in the “Reducing HIV-Related Health Disparities” chapter that: 
By the end of 2011, CDC will:  
 Conduct consultation with HRSA to develop recommendations for gathering and 
reporting data to calculate CVL. 
 In consultation with States, provide technical assistance to localities, particularly those 
with a heavy disease burden, to collect necessary data to calculate community viral load. 
Furthermore, the National HIV/AIDS Strategy establishes national targets—by end of 2015:  
 Increase the proportion of HIV-diagnosed gay and bisexual men with undetectable viral 
load by 20 percent.  
 Increase the proportion of HIV-diagnosed blacks with undetectable viral load by 20 
percent.  
 Increase the proportion of HIV-diagnosed Latinos with undetectable viral load by 20 
percent.  
On March 9–10, 2011, a consultation on “Monitoring and Use of Laboratory Data Reported to 
HIV Surveillance” was hosted by CDC and HRSA. The recommendations from that consultation 
will become available in 2011. 
  
                                                            
10 National HIV/AIDS strategy for the United States. http://www.whitehouse.gov/ONAP. Published July 2010. Accessed August 25, 2011. 
11 National HIV/AIDS strategy for the United States. Federal implementation plan. http://www.whitehouse.gov/files/documents/ 
nhas-implementation.pdf. Published July 2010. Accessed August 25, 2011. 
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Sample size required to detect the difference of GM between two subpopulation groups 
April 21, 2011 
Suppose that we would like to have a power of W (say 80% chance) to detect a difference that 
one group has a GM at least as k fold high as the GM of the other group.  
Null hypothesis: GM1 = GM2 or GMmax/GMmin = 1  
where GMmax = max(GM1, GM2) and GMmin = min(GM1, GM2) 
Alternative hypothesis: GM1 ≠ GM2 or GMmax / GMmin > 1 
Test statistic:  
1
10 ⁄  
where SE is the pooled standard error estimate given by 
⁄ ⁄  
The p-value for this test is given by 1  where Z ~ Normal (0,1) 
and  is the inverse function of the standard normal distribution 
Given the type I error rate  (e.g., 0.05) and the difference desired to detect: GMmax / GMmin = k, 
the power or the probability to detect this difference can be calculated as 
1 1⁄ 1⁄⁄  
where S is the expected standard deviation of log10(VL) in the population of interest. 
When n1 = n2 = n, we have 
1 2⁄⁄  
Given the type I error rate (), the relative difference to detect (k), the expected standard 
deviation of log10(VL) (S), and the desired power (W), the required sample size is 
2 1 1 ⁄  
The required sample sizes are listed in Table 1a for W = 0.8 and Table 1b for W = 0.9 with  = 
0.05 and various S and k. 
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History  
On March 16, 2010, staff from the HIV Incidence and Case Surveillance Branch of CDC initiated 
a Community Viral Load Workgroup composed of HIV surveillance coordinators experienced 
and/or interested in estimating community viral load in their area. The purpose of the Workgroup 
was to develop recommendations for estimating community viral load at the local, state, and 
national level. The Workgroup had 10 calls between March 16, 2010 and April 27, 2011.  
During these calls, participants reviewed current methods being used for calculating community 
viral load, definitions, estimation assumptions, strengths and weaknesses of estimates, and 
representativeness of the data used to produce the estimates. Participation in the Workgroup grew 
from 8 city and state health department staff (Chicago, District of Columbia, Los Angeles, 
Maryland, Minnesota, New York City, San Francisco, and Washington) on the first call to 26 
city/state health departments on the last calls (California, Colorado, Connecticut, Florida, Georgia, 
Houston, Kentucky, Louisiana, New York State, North Carolina, Oregon, Pennsylvania, 
Philadelphia, South Carolina, Tennessee, Texas, Virginia, and Wisconsin).  
A sub-working group was formed to discuss the details for the final recommendations. There were 
four sub-working group calls and its active members included: California, Chicago, District of 





ART:  antiretroviral treatment or therapy. 
ARV:  antiretroviral; usually used in association with treatment or medication use. 
Categorical VL measures:  categories of VL measurement that are useful indicators. 
Standardized categorical measures include: percentage suppressed/not suppressed, percentage 
undetectable, and percentage high VLs. 
Component VL measures:  boxed groups described in Figure 2. They include: A. In care and 
with undetectable VL; B. In care with detectable VL; C. In care, no VL; D. Diagnosed but not in 
care; and E. Undiagnosed. 
CVL:  community viral load. 
eHARS:  standardized HIV surveillance database used by all jurisdictions. It is a relational 
database that is document-based. 
Jurisdictional case:  person diagnosed with HIV or AIDS while a resident of the jurisdiction 
Lag time:  delay between the occurrence of an event and when the event is known or reported; 
e.g., deaths in 2009 may not be recorded until 2010 because there is an 18-month lag time for 
≥90% of deaths in 2009 to be recognized and captured in a database. 
Log10=log base 10:  the logarithm for base 10 is the exponent; e.g., the logarithm of 1000 to base 
10 is 3. The log10 transformation of a viral load of 1000 copies/mL is 3. 
MMP:  Medical Monitoring Project (MMP) is a nationally representative surveillance system 
administered by CDC among HIV-infected persons that are receiving medical care for their HIV 
disease. 
Multiple imputation:  analytic process in which missing data are populated with values based on 
existing data through multiple rounds of data simulations. 
NDI:  National Death Index. See Vital Statistics for an explanation. 
Resident case:  HIV-infected person currently residing in a jurisdiction. Not all residential cases 
are jurisdictional cases (see definition above) as persons may be diagnosed in one jurisdiction but 
move to another. 
SAS:  software in wide use for statistical analyses of HIV surveillance data. 
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Soundex:  4-character alphanumeric “code” that is based on the sound or pronunciation of an 
individual’s last name. Soundex is used instead of name to identify a case along with demographic 
information. 
SSDI:  Social Security Death Index is based on the national Social Security Death Master File, 
which includes death information (name, social security number, date of death, possibly residence 
at time of death) for most persons that have a Social Security number. The SSDI is updated 
quarterly. 
Viral load (VL):  measure of the concentration of viral particles per volume of blood. The unit of 
measurement for HIV viral load is copies per milliliter or copies/mL. 
Viremia:  presence of virus in the blood. 
Vital statistics:  collection of birth, death, and marriage information; local jurisdictions collect or 
receive this information. For this document, death data are the focus. Death certificates, which 
include cause of death information, are collected by local Vital Statistics departments. States 
aggregate local death information and then provide this data to CDC’s National Center for Health 
Statistics, where a national death dataset is created and cause of death information are recoded to 
provide uniformity across states. The national dataset is called the National Death Index or NDI. 
 
